Alpha-fetoprotein (AFP), the most frequently used serum biomarker in the surveillance and diagnosis of HCC in clinical practice, is characterized by low diagnostic performance, especially during early-stage HCC, indicating an unmet need for developing effective new biomarkers for HCC detection, which could complement or even replace AFP [4,5,15]. This evidence concerns the gene AFP and hepatocellular carcinoma.